Travere Therapeutics, Inc.
TVTXHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframePart of the healthcare sector, Travere Therapeutics, Inc. (TVTX) is listed under Biotechnology. At a $3.99B market cap, Travere Therapeutics, Inc. ranks as a mid-cap company within healthcare. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Market Cap
$3.99B
Beta
1.14
P/E (TTM)
—
P/E (Fwd)
8.73
EPS (TTM)
$-0.50
EPS (Fwd)
$4.92
ROE
-69.4%
ROA
-6.5%
Cash
$264.7M
Total Debt
$327.7M
Free CF
-$51.2M
52W Change
182.3%
Annual Financials
Cash vs Debt
On the balance sheet, TVTX has $264.7M in cash with $327.7M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$51.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -69.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $109.5M (2022) to $490.7M (2025), reflecting a 348% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing TVTX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.